(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance...
Stats | |
---|---|
今日成交量 | 1.27M |
平均成交量 | 1.57M |
市值 | 0.00 |
EPS | $0 ( 2021-08-03 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0.734 (2.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-07-15 | Hoerter Steven L. | Sell | 26 342 | Stock Option (right to buy) |
2021-07-15 | Reeve Emma | Sell | 60 000 | Stock Option (Right to Buy) |
2021-07-15 | Reeve Emma | Sell | 37 527 | Stock Option (right to buy) |
2021-07-15 | Reeve Emma | Sell | 73 428 | Stock Option (right to buy) |
2021-07-15 | Reeve Emma | Sell | 11 777 | Stock Option (right to buy) |
INSIDER POWER |
---|
0.00 |
Last 99 transactions |
Buy: 291 157 | Sell: 1 004 317 |
音量 相关性
Constellation 相关性 - 货币/商品
Constellation 财务报表
Annual | 2020 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-4.49 |
FY | 2020 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-4.49 |
FY | 2019 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-3.04 |
FY | 2018 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-5.00 |
Financial Reports:
No articles found.
Constellation
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. The company is also developing CPI-0209 that is in Phase I dose escalation portion of a Phase I/II clinical trial to treat solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。